Description: Invion Limited is a clinical-stage life sciences (drug development) company. The Company is engaged in the completion of clinical development programs and targeted business development programs associated with its approximately three drug assets, such as INV102 (nadolol), INV103 (ala-Cpn10) and INV104 (zafirlukast). It focuses on the development of treatments for opportunities in chronic inflammatory and respiratory disease. INV102 (nadolol) is a beta adrenergic biased ligand targeted to treat chronic inflammatory airway diseases via the reversal of mucous metaplasia in the airway epithelium. INV104 (zafirlukast) is a leukotriene receptor antagonist (LTRA) that reduces inflammation, constriction of the airways, and the build-up of mucus in the lungs. INV103 (ala-Cpn10) is a modified, naturally occurring human protein, which has been proposed as a founding member of the Resolution Associated Molecular Pattern (RAMPs) family hypothesized to maintain and restore immune homeostasis.
Home Page: www.inviongroup.com
IVX Technical Analysis
100 Albert Road
Melbourne,
VIC
3205
Australia
Phone:
61 3 9692 7222
Officers
| Name | Title |
|---|---|
| Mr. Thian Chew | Exec. Chairman & CEO |
| Ms. Melanie Jaye Leydin B.Bus, C.A., CA | Chief Financial Officer |
| Dr. Dean Naylor | Head of Intellectual Property Devel. |
| Ms. Claire Newstead-Sinclair BBus, C.A., CA | Company Sec. |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.9512 |
| Price-to-Sales TTM: | 19.5035 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |